Your browser is no longer supported. Please, upgrade your browser.
Halozyme Therapeutics, Inc.
Index- P/E25.78 EPS (ttm)1.56 Insider Own0.90% Shs Outstand142.49M Perf Week-4.16%
Market Cap5.97B Forward P/E15.38 EPS next Y2.62 Insider Trans-22.18% Shs Float139.67M Perf Month-1.78%
Income228.70M PEG1.36 EPS next Q0.42 Inst Own94.60% Short Float4.10% Perf Quarter-10.74%
Sales412.50M P/S14.48 EPS this Y282.30% Inst Trans-1.94% Short Ratio7.79 Perf Half Y-2.70%
Book/sh0.84 P/B47.96 EPS next Y58.15% ROA29.50% Target Price52.27 Perf Year56.53%
Cash/sh5.09 P/C7.91 EPS next 5Y19.00% ROE209.20% 52W Range25.47 - 56.40 Perf YTD-5.67%
Dividend- P/FCF39.96 EPS past 5Y41.10% ROI26.30% 52W High-28.56% Beta1.44
Dividend %- Quick Ratio8.20 Sales past 5Y14.70% Gross Margin82.30% 52W Low58.19% ATR1.19
Employees136 Current Ratio8.80 Sales Q/Q147.30% Oper. Margin58.40% RSI (14)42.12 Volatility2.58% 2.72%
OptionableYes Debt/Eq7.31 EPS Q/Q231.40% Profit Margin55.40% Rel Volume0.95 Prev Close40.29
ShortableYes LT Debt/Eq6.56 EarningsAug 09 AMC Payout0.00% Avg Volume735.10K Price40.29
Recom2.20 SMA20-3.42% SMA50-2.40% SMA200-8.05% Volume0 Change0.00%
Jun-14-21Initiated Evercore ISI Outperform
May-17-21Initiated SVB Leerink Outperform $56
May-11-21Downgrade Piper Sandler Overweight → Neutral $50 → $48
Jan-21-21Reiterated The Benchmark Company Buy $46 → $59
Dec-17-20Initiated Berenberg Buy $50
Sep-14-20Resumed JP Morgan Overweight $28
Jul-01-20Initiated The Benchmark Company Buy $39
Feb-05-20Upgrade Piper Sandler Neutral → Overweight $18 → $27
Jan-09-20Upgrade BMO Capital Markets Market Perform → Outperform $17 → $24
Jan-08-20Initiated Goldman Buy $24
Nov-05-19Upgrade Barclays Underweight → Equal Weight $17 → $16
Oct-19-18Resumed Piper Jaffray Neutral
May-11-18Downgrade Barclays Equal Weight → Underweight $19
Jan-24-18Initiated Goldman Neutral
Oct-16-17Reiterated Piper Jaffray Overweight $26 → $29
Jan-06-17Downgrade Citigroup Buy → Neutral
Nov-03-16Initiated Deutsche Bank Buy $12
Dec-04-15Initiated Wells Fargo Outperform
Nov-18-15Initiated Citigroup Buy
Sep-22-15Initiated Barclays Overweight $27
Sep-15-21 04:05PM  
Sep-08-21 11:30AM  
Aug-26-21 09:00AM  
Aug-10-21 09:45AM  
Aug-09-21 10:00PM  
Aug-05-21 08:37AM  
Aug-02-21 03:01PM  
Jul-30-21 08:00AM  
Jul-27-21 04:05PM  
Jul-23-21 06:12AM  
Jul-19-21 11:21PM  
Jul-12-21 09:09AM  
Jun-23-21 09:37AM  
Jun-22-21 01:48PM  
Jun-17-21 05:14AM  
Jun-09-21 11:30AM  
Jun-01-21 04:01PM  
May-28-21 04:40PM  
May-21-21 10:02AM  
May-11-21 11:09AM  
May-10-21 11:30PM  
Apr-29-21 04:05PM  
Apr-22-21 03:19PM  
Apr-20-21 04:05PM  
Apr-04-21 06:12AM  
Mar-25-21 11:30AM  
Mar-19-21 09:43AM  
Mar-17-21 01:10PM  
Mar-04-21 07:05AM  
Feb-24-21 10:41PM  
Feb-23-21 10:30PM  
Feb-22-21 10:07AM  
Feb-10-21 04:05PM  
Jan-15-21 05:30PM  
Jan-14-21 10:46AM  
Jan-13-21 02:17PM  
Jan-12-21 01:24PM  
Jan-11-21 11:22AM  
Jan-08-21 09:57AM  
Jan-06-21 11:13AM  
Jan-05-21 10:59AM  
Jan-04-21 08:00AM  
Dec-31-20 08:52AM  
Dec-23-20 01:30PM  
Dec-21-20 10:01AM  
Dec-19-20 03:52AM  
Dec-16-20 12:00PM  
Dec-14-20 01:05PM  
Dec-10-20 12:47PM  
Dec-09-20 10:42AM  
Dec-08-20 01:32PM  
Dec-04-20 08:50AM  
Dec-02-20 11:30AM  
Nov-27-20 12:00PM  
Nov-25-20 01:14PM  
Nov-24-20 03:08PM  
Nov-23-20 09:12AM  
Nov-18-20 04:01PM  
Nov-17-20 01:16PM  
Nov-13-20 09:59AM  
Nov-12-20 08:15AM  
Nov-05-20 06:40PM  
Nov-04-20 06:54AM  
Nov-03-20 04:14PM  
Nov-02-20 11:31PM  
Oct-26-20 12:31PM  
Oct-22-20 07:30PM  
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its proprietary product include Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company is also developing Perjeta for breast cancer; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ALXN1210 and ALXN1810 subcutaneous formulations; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; and Centre for the AIDS Programme of Research in South Africa. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Torley HelenPresident and CEOSep 07Option Exercise14.6650,000733,000587,160Sep 07 05:46 PM
Torley HelenPresident and CEOSep 07Sale42.3850,0002,118,846537,160Sep 07 05:46 PM
Matsuda MasaruSVP, General CounselSep 04Option Exercise0.006,883023,461Sep 07 05:42 PM
BIZZARI JEAN-PIERREDirectorAug 25Sale41.0135,0001,435,45552,544Aug 25 05:54 PM
Torley HelenPresident and CEOAug 10Option Exercise14.6650,000733,000587,160Aug 10 07:01 PM
Torley HelenPresident and CEOAug 10Sale41.1150,0002,055,576537,160Aug 10 07:01 PM
LaBarre Michael J.SVP, Chief Technical OfficerJul 15Option Exercise6.5514,68596,187148,796Jul 15 07:36 PM
Torley HelenPresident and CEOJul 06Option Exercise14.6650,000733,000587,160Jul 06 06:09 PM
Torley HelenPresident and CEOJul 06Sale45.9750,0002,298,650537,160Jul 06 06:09 PM
LaBarre Michael J.SVP, Chief Technical OfficerJul 01Option Exercise6.5540,315264,063174,426Jul 06 05:19 PM
LaBarre Michael J.SVP, Chief Technical OfficerJul 01Sale45.7040,3151,842,315134,111Jul 06 05:19 PM
Torley HelenPresident and CEOJun 07Option Exercise14.6650,000733,000587,160Jun 07 06:53 PM
Torley HelenPresident and CEOJun 07Sale39.6650,0001,982,950537,160Jun 07 06:53 PM
Torley HelenPresident and CEOMay 11Option Exercise14.6650,000733,000587,160May 11 06:22 PM
Torley HelenPresident and CEOMay 11Sale43.0250,0002,151,099537,160May 11 06:22 PM
LaBarre Michael J.SVP, Chief Technical OfficerMay 03Option Exercise11.2911,311127,701134,111May 03 08:27 PM
Kelley Kenneth JDirectorApr 14Sale45.005,000225,000179,833Apr 14 04:19 PM
Torley HelenPresident and CEOApr 05Option Exercise14.6650,000733,000587,160Apr 05 07:51 PM
Torley HelenPresident and CEOApr 05Sale42.5550,0002,127,250537,160Apr 05 07:51 PM
Sun Elaine DSVP, Chief Financial OfficerMar 02Option Exercise0.0012,166012,166Mar 02 07:15 PM
Torley HelenPresident and CEOMar 01Option Exercise14.6650,000733,000587,160Mar 01 08:03 PM
Kelley Kenneth JDirectorMar 01Sale45.345,000226,717184,833Mar 01 08:08 PM
LaBarre Michael J.SVP, Chief Technical OfficerMar 01Sale45.8118,324839,364122,800Mar 01 08:06 PM
Torley HelenPresident and CEOMar 01Sale46.1950,0002,309,454537,160Mar 01 08:03 PM
LaBarre Michael J.SVP, Chief Technical OfficerFeb 22Option Exercise0.008,8030145,488Feb 22 06:28 PM
Torley HelenPresident and CEOFeb 22Option Exercise0.0039,3540556,671Feb 22 06:27 PM
Torley HelenPresident and CEOFeb 14Option Exercise0.0028,7290531,560Feb 16 04:52 PM
Torley HelenPresident and CEOFeb 12Option Exercise0.0032,7950519,090Feb 12 07:06 PM
LaBarre Michael J.SVP, Chief Technical OfficerFeb 12Option Exercise0.007,8830135,911Feb 12 07:07 PM
Matsuda MasaruSVP, General CounselFeb 12Option Exercise0.004,129018,625Feb 12 07:10 PM
Matsuda MasaruSVP, General CounselFeb 10Option Exercise0.006,257017,699Feb 12 07:10 PM
LaBarre Michael J.SVP, Chief Technical OfficerFeb 10Option Exercise0.008,1340130,934Feb 12 07:07 PM
Torley HelenPresident and CEOFeb 10Option Exercise0.0031,2820501,804Feb 12 07:06 PM
Torley HelenPresident and CEOFeb 01Option Exercise14.6650,000733,000520,522Feb 01 06:55 PM
Kelley Kenneth JDirectorFeb 01Sale48.125,000240,594189,833Feb 01 06:56 PM
Torley HelenPresident and CEOFeb 01Sale47.8450,0002,391,918470,522Feb 01 06:55 PM
Kelley Kenneth JDirectorJan 04Sale42.915,000214,556194,833Jan 04 05:07 PM
LaBarre Michael J.SVP, Chief Technical OfficerDec 21Sale42.5812,000510,919122,800Dec 21 06:01 PM
Kelley Kenneth JDirectorDec 07Sale41.0035,0861,438,526199,833Dec 07 06:05 PM
Kelley Kenneth JDirectorDec 02Sale41.0031,7921,303,472234,919Dec 02 05:55 PM
Kelley Kenneth JDirectorNov 27Sale41.2510,000412,500266,711Nov 27 05:43 PM
Torley HelenPresident and CEONov 25Option Exercise14.6650,000733,000530,522Nov 25 06:56 PM
Kelley Kenneth JDirectorNov 25Sale41.509,671401,350276,711Nov 27 05:43 PM
Daly James MDirectorNov 25Sale40.4110,363418,80021,002Nov 25 06:57 PM
Henderson Jeffrey WilliamDirectorNov 25Sale40.0824,498981,75747,609Nov 25 06:59 PM
Torley HelenPresident and CEONov 25Sale40.7350,0002,036,568480,522Nov 25 06:56 PM
LaBarre Michael J.SVP, Chief Technical OfficerNov 20Sale38.7612,000465,176134,800Nov 20 06:25 PM
LaBarre Michael J.SVP, Chief Technical OfficerOct 20Sale30.4312,000365,148146,800Oct 20 04:53 PM